Detecting Cancer Before Symptoms: How GRAIL’s Galleri Test Is Transforming Early Detection with Trudy McKanna, Senior Field Medical Director for GRAIL

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com Early cancer detection significantly increases survival rates and reduces the overall health and financial burden. In this episode, Trudy McKanna, Senior Field Medical Director for GRAIL, discusses how Galleri multi-cancer early detection technology is transforming screening by identifying signals for more than 50 cancers through a simple blood draw. She explains how methylation patterns, cell-free DNA, and machine learning allow clinicians to pinpoint potential cancer origins before symptoms appear. Trudy shares data showing that adding this test to standard screening detects seven times more cancers, with over half found at early stages, while maintaining a remarkably low false-positive rate. She also highlights its impact on underserved communities, population health scalability, and the importance of rigorous clinical validation.  Tune in and discover how early detection can transform cancer outcomes! Resources Connect with and follow Trudy McKanna on LinkedIn. Follow GRAIL on LinkedIn and visit their website! Learn more about Galleri here.